Bioregulatory therapy for chronic abacterial prostatitis

BACKGROUND: Chronic abacterial prostatitis/chronic pelvic pain syndrome (CAP/CPPS) is the most common form of chronic prostatitis.
 AIM: The aim study was to evaluate effectiveness and tolerability complex therapy in patients with CAP/CPPS using bioregulatory peptide drug Uroprost-D.
 MATERIALS AND METHODS: included 47 men aged 23 54 years (mean 38.1 7.2 years) (category III according NYHA classification, 1995). Patients 1st group (n = 24) were prescribed alpha-blocker tamsulosin 0.4 mg for 30 days rectal suppositories Uroprost-D one per day 15 days. 2nd 23) also indomethacin 100 mg, dynamics clinical parameters assessed on 15, 60th from start study.
 RESULTS: By 15th study, there a significant positive symptoms both groups. 30th treatment effect persisted, while increased, which expressed an increase scores Pain domains total score NIH-CPSI questionnaire. This trend even more pronounced by observation, when difference found questionnaire separately Pain, Dysuria Quality life. During no statistically changes maximum urine flow rate, prostate volume residual volume. Tolerability satisfactory, frequency negative manifestations slightly higher group.
 CONCLUSIONS: use CAP accompanied decrease severity dysuria. appointment seems be pathogenetically justified alternative NSAIDs this category patients.